Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$37.69

0.88 (2.39%)

06:21
01/22/19
01/22
06:21
01/22/19
06:21

Boston Scientific announces Vici stent meets primary endpoint in VIRTUS trial

Boston Scientific announced positive 12-month data demonstrating that patients who were treated with the Vici Venous Stent System for iliac and femoral vein obstructions exhibited a high rate of patent, or open, target lesions. Primary safety and efficacy results from the VIRTUS trial were presented as a first-time data release at the Leipzig Interventional Course, or LINC. The VIRTUS trial evaluated the Vici stent in patients with clinically significant obstructions in the illiofemoral venous outflow tract resulting from Post Thrombotic Syndrome, or PTS, or compressive diseases such as May-Thurner syndrome. These conditions impact the veins located deep in the pelvis and if left untreated, can impair blood flow back to the heart and cause blood to pool in the legs, resulting in pain, swelling and ulceration. In the VIRTUS trial, the Vici stent met its primary effectiveness endpoint with a primary patency rate of 84% at 12-months, which was greater than the pre-defined performance goal, or PGE, of 72.1%. Nearly all the patients treated with the VICI stent, 98.8%, were free from major adverse events at 30 days post-procedure, thus surpassing the pre-defined safety performance goal of 94%.

  • 27

    Jan

  • 06

    Feb

  • 18

    May

  • 28

    May

BSX Boston Scientific
$37.69

0.88 (2.39%)

01/16/19
ADAM
01/16/19
NO CHANGE
Target $186
ADAM
Buy
Edwards Lifesciences price target raised to $186 from $177 at Canaccord
Canaccord analyst Jason Mills raised his price target on Edwards Lifesciences (EW) to $186 from $177 following its litigation settlement with Boston Scientific (BSX). The analyst views the settlement as highly positive for Edwards and a net positive for Boston Scientific over the longer-term. Mills reiterated his Buy rating on Edwards Lifesciences shares.
01/08/19
PIPR
01/08/19
NO CHANGE
Target $40
PIPR
Overweight
Boston Scientific shares should trade higher after Q4 results, says Piper
Piper Jaffray analyst Matt O'Brien reiterated an Overweight rating and $40 price target on Boston Scientific after the company reported preliminary Q4 revenue at the high end of previously issued guidance of $2.525B-$2565B. In a research note to investors, O'Brien says he is "encouraged" after the preliminary Q4 and sees the stock up "a bit" today, adding that the company's quarter was "solid" with trends moving int he right direction. He continues to see upside to numbers, which, along with a steady multiple, should push shares higher.
01/03/19
RBCM
01/03/19
NO CHANGE
Target $42
RBCM
Top Pick
Boston Scientific remains Top Pick at RBC Capital after 'stellar 2018'
RBC Capital analyst Glenn Novarro maintained his Top Pick rating and $42 price target on Boston Scientific following the company's "stellar" 2018 that saw its stock price rise 43%. The analyst cites the company's "strong organic revenue and EPS growth, healthy free cash flow, and a deep pipeline" driving the share gains last year, and he expects 2019 to "unfold much like 2018 did". With the new year expected to be highlighted by product launches and enhancements, Novarro believes that the initial "conservative guidance" will position Boston Scientific to beat and raise quarterly earnings, sustaining the premium valuation of its stock.
01/02/19
SBSH
01/02/19
NO CHANGE
SBSH
Citi makes four rating changes in Medical Devices, 'warning up' to J&J
Citi analyst Amit Hazan issued his 2019 preview for Medical Devices, which included four rating changes. The analyst upgraded both Zimmer Biomet (ZBH) and Baxter International (BAX) to Buy from Neutral, downgraded Medtronic (MDT) to Neutral from Buy and downgraded Abbott Laboratories (ABT) to Sell from Neutral. He also kept Buy ratings on Intuitive Surgical (ISRG) and Boston Scientific (BSX), but adds he's "relatively more cautious." Further, Hazan kept a Sell rating on Edwards Lifesciences (EW) and says he's "warming up" to Neutral-rated Johnson & Johnson (JNJ). The analyst expects "fairly stable" fundamentals for the group in 2019, with "modest slowdowns" in organic sales and earnings growth.

TODAY'S FREE FLY STORIES

03:50
03/20/19
03/20
03:50
03/20/19
03:50
General news
FX Update: The dollar has been trading steady-to-firmer »

FX Update: The dollar…

CREE

Cree

$57.27

0.36 (0.63%)

03:42
03/20/19
03/20
03:42
03/20/19
03:42
Upgrade
Cree rating change  »

Cree upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

NOMD

Nomad Foods

$20.82

-0.63 (-2.94%)

03:27
03/20/19
03/20
03:27
03/20/19
03:27
Syndicate
Nomad Foods 17.39M share Secondary priced at $20.00 »

The deal size was reduced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

CDAY

Ceridian

$50.75

0.94 (1.89%)

03:26
03/20/19
03/20
03:26
03/20/19
03:26
Syndicate
Ceridian 13M share Secondary priced at $50.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 20

    Mar

ATTO

Atento

$3.95

0.06 (1.54%)

20:51
03/19/19
03/19
20:51
03/19/19
20:51
Earnings
Atento reports Q4 recurring EPS 21c, consensus 17c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

TRHC

Tabula Rasa HealthCare

$60.28

1.35 (2.29%)

20:47
03/19/19
03/19
20:47
03/19/19
20:47
Recommendations
Tabula Rasa HealthCare analyst commentary at Piper Jaffray »

Tabula Rasa HealthCare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

GIS

General Mills

$47.24

-0.365 (-0.77%)

20:25
03/19/19
03/19
20:25
03/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

TRN

Trinity Industries

$22.46

-0.25 (-1.10%)

20:20
03/19/19
03/19
20:20
03/19/19
20:20
Hot Stocks
Trinity Industries names Leldon Echols chairman of the board »

Trinity Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Mar

TIGR

UP Fintech

$0.00

(0.00%)

20:06
03/19/19
03/19
20:06
03/19/19
20:06
Syndicate
UP Fintech 13M share IPO priced at $8.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

SND

Smart Sand

$4.27

-0.4 (-8.57%)

20:01
03/19/19
03/19
20:01
03/19/19
20:01
Initiation
Smart Sand initiated at B. Riley FBR »

Smart Sand initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LYFT

Lyft

$0.00

(0.00%)

20:00
03/19/19
03/19
20:00
03/19/19
20:00
Initiation
Lyft initiated at DA Davidson »

Lyft initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

DERM

Dermira

$14.13

1.52 (12.05%)

19:40
03/19/19
03/19
19:40
03/19/19
19:40
Syndicate
Dermira 9.8M share Secondary priced at $13.25 per share »

Citi, Cowen, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:38
03/19/19
03/19
19:38
03/19/19
19:38
Upgrade
Nevro rating change at BMO Capital »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

TORC

ResTORbio

$7.16

-1.81 (-20.18%)

19:34
03/19/19
03/19
19:34
03/19/19
19:34
Syndicate
ResTORbio 7.2M share Secondary priced at $6.95 »

BofA/Merrill, SVB Leerink…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

NVRO

Nevro

$44.76

0.37 (0.83%)

19:33
03/19/19
03/19
19:33
03/19/19
19:33
Upgrade
Nevro rating change at BMO Capital »

Nevro upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

PFE

Pfizer

$42.32

0.51 (1.22%)

, MKGAY

Merck KGaA

$0.00

(0.00%)

19:17
03/19/19
03/19
19:17
03/19/19
19:17
Hot Stocks
Pfizer, Merck KGaA discontinue Phase III JAVELIN Ovarian PARP study »

Merck KGaA (MKGAY) and…

PFE

Pfizer

$42.32

0.51 (1.22%)

MKGAY

Merck KGaA

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 30

    Apr

  • 18

    May

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:11
03/19/19
03/19
19:11
03/19/19
19:11
Hot Stocks
Google outlines changes to Android mobile options, ad formats in Europe »

Google said in a blog…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:08
03/19/19
03/19
19:08
03/19/19
19:08
Periodicals
Google offers Android, product ad concessions for Europe, WSJ says »

Google intends to ask all…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

, SCS

Steelcase

$17.49

-0.115 (-0.65%)

19:06
03/19/19
03/19
19:06
03/19/19
19:06
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

SCS

Steelcase

$17.49

-0.115 (-0.65%)

AUPH

Aurinia Pharmaceuticals

$6.40

0.13 (2.07%)

NVRO

Nevro

$44.76

0.37 (0.83%)

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

TME

Tencent Music

$18.65

-0.48 (-2.51%)

WPRT

Westport

$1.50

(0.00%)

AIR

AAR Corp.

$35.10

(0.00%)

FDX

FedEx

$181.50

-0.92 (-0.50%)

FNV

Franco-Nevada

$75.64

0.035 (0.05%)

PRNB

Principia Biopharma

$36.88

0.48 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 01

    Apr

  • 02

    Apr

  • 05

    Apr

  • 14

    May

  • 28

    May

  • 24

    Jun

  • 26

    Jun

LGIH

LGI Homes

$54.89

-2.27 (-3.97%)

19:02
03/19/19
03/19
19:02
03/19/19
19:02
Hot Stocks
LGI Homes announces new community in Las Vegas »

LGI Homes, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

19:01
03/19/19
03/19
19:01
03/19/19
19:01
Hot Stocks
Sage says Zulresso approval represents 'game-changing approach' to PPD »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

QTRX

Quanterix

$24.59

-0.01 (-0.04%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Quanterix »

Quanterix files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIHS

Senmiao Technology

$4.71

-0.275 (-5.52%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Senmiao Technology »

Senmiao Technology files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:54
03/19/19
03/19
18:54
03/19/19
18:54
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

PULM

Pulmatrix

$1.70

-0.09 (-5.03%)

18:53
03/19/19
03/19
18:53
03/19/19
18:53
Syndicate
Breaking Syndicate news story on Pulmatrix »

Pulmatrix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.